Clinical Course and Outcomes of COVID-19 Infection in Patients Treated with Rituximab: A Tertiary Care Center Experience

References

• Alhowaish TS, Alhamadh MS, Alhabeeb AY, et al. Outcomes of COVID-19 in inflammatory rheumatic diseases: a retrospective cohort study. Cureus. 2022;14(6). doi:10.7759/CUREUS.26343
   Web of Science ®Google Scholar
• Kaegi C, Wuest B, Schreiner J, et al. Systematic review of safety and efficacy of rituximab in treating immune-mediated disorders. Front Immunol. 2019;10:1990. doi:10.3389/FIMMU.2019.01990/BIBTEX
   PubMed Web of Science ®Google Scholar
• Loarce-Martos J, García-Fernández A, López-Gutiérrez F, et al. High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study. Rheumatol Int. 2020;40(12):2015–2021. doi:10.1007/S00296-020-04699-X/TABLES/2
   PubMed Web of Science ®Google Scholar
• Pablos JL, Galindo M, Carmona L, et al. Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. Ann Rheum Dis. 2020;79(12):1544–1549. doi:10.1136/ANNRHEUMDIS-2020-218296
   PubMed Web of Science ®Google Scholar
• Hsu CY, Ko CH, Wang JL, Hsu TC, Lin CY. Comparing the burdens of opportunistic infections among patients with systemic rheumatic diseases: a nationally representative cohort study. Arthritis Res Ther. 2019;21(1):1–10. doi:10.1186/S13075-019-1997-5/TABLES/5
   PubMed Web of Science ®Google Scholar
• Nuño L, Novella Navarro M, Bonilla G, et al. Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases. Ann Rheum Dis. 2020;79(12):1659–1661. doi:10.1136/ANNRHEUMDIS-2020-218054
   PubMed Web of Science ®Google Scholar
• Schulze-Koops H, Krueger K, Vallbracht I, Hasseli R, Skapenko A. Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab. Ann Rheum Dis. 2021;80(5):e67–e67. doi:10.1136/ANNRHEUMDIS-2020-218075
   PubMed Web of Science ®Google Scholar
• MacKenna B, Kennedy NA, Mehrkar A, et al. Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform. Lancet Rheumatol. 2022;4(7):e490–e506. doi:10.1016/S2665-9913(22)00098-4
   PubMedGoogle Scholar
• Tepasse PR, Hafezi W, Lutz M, et al. Persisting SARS‐CoV‐2 viremia after rituximab therapy: two cases with fatal outcome and a review of literature. Br J Haematol. 2020;190(2):185–188. doi:10.1111/BJH.16896
   PubMed Web of Science ®Google Scholar
• Alpizar-Rodriguez D, Irazoque-Palazuelos F, Rodriguez-Reyne TS, et al. POS1242 FACTORS ASSOCIATED WITH MORTALITY IN PATIENTS WITH RHEUMATIC DISEASES AND COVID-19 IN MEXICO. Ann Rheum Dis. 2021;80(Suppl 1):904. doi:10.1136/ANNRHEUMDIS-2021-EULAR.3342
   Google Scholar
• Ekin A, Coskun BN, Dalkilic E, Pehlivan Y. The effects of COVID-19 infection on the mortality of patients receiving rituximab therapy. Ir J Med Sci. 2022;1. doi:10.1007/S11845-022-03193-6
   Web of Science ®Google Scholar
• Singh N, Madhira V, Hu C, et al. Rituximab is associated with worse COVID-19 outcomes in patients with rheumatoid arthritis: a retrospective, nationally sampled cohort study from the U.S. National COVID Cohort Collaborative (N3C). Semin Arthritis Rheum. 2023:58. doi:10.1016/J.SEMARTHRIT.2022.152149
   Web of Science ®Google Scholar
• Sarzi-Puttini P, Giorgi V, Sirotti S, et al. COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome? Clin Exp Rheumatol. 2020;38(2):337–342.
   PubMed Web of Science ®Google Scholar
• Law HKW, Chung YC, Hoi YN, et al. Chemokine up-regulation in SARS-coronavirus-infected, monocyte-derived human dendritic cells. Blood. 2005;106(7):2366–2374. doi:10.1182/BLOOD-2004-10-4166
   PubMed Web of Science ®Google Scholar
• Montero F, Martínez-Barrio J, Serrano-Benavente B, et al. Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes. Rheumatol Int. 2020;40(10):1593–1598. doi:10.1007/S00296-020-04676-4
   PubMed Web of Science ®Google Scholar
• Sharmeen S, Elghawy A, Zarlasht F, Yao QP. COVID-19 in rheumatic disease patients on immunosuppressive agents. Semin Arthritis Rheum. 2020;50(4):680. doi:10.1016/J.SEMARTHRIT.2020.05.010
   PubMed Web of Science ®Google Scholar
• Avouac J, Drumez E, Hachulla E, et al. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. Lancet Rheumatol. 2021;3(6):e419–e426. doi:10.1016/S2665-9913(21)00059-X
   PubMedGoogle Scholar
• Sterne JAC, Murthy S, J V. D, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020;324(13):1. doi:10.1001/JAMA.2020.17023
   Web of Science ®Google Scholar
• Florence A, Nassim AA, Jean-David A, et al. Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients. Ann Rheum Dis. 2021;80(4):527. doi:10.1136/ANNRHEUMDIS-2020-218310
   PubMed Web of Science ®Google Scholar
• Gianfrancesco M, Hyrich KL, Hyrich KL, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry. Ann Rheum Dis. 2020;79(7):859–866. doi:10.1136/ANNRHEUMDIS-2020-217871
   PubMed Web of Science ®Google Scholar
• Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720. doi:10.1056/NEJMOA2002032
   PubMed Web of Science ®Google Scholar
• Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020;323(16):1574. doi:10.1001/JAMA.2020.5394
   PubMed Web of Science ®Google Scholar
• Thiel J, Rizzi M, Engesser M, et al. B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients. Arthritis Res Ther. 2017;19(1). doi:10.1186/S13075-017-1306-0
   PubMedGoogle Scholar
• Cooper N, Davies EG, Thrasher AJ. Repeated courses of rituximab for autoimmune cytopenias may precipitate profound hypogammaglobulinaemia requiring replacement intravenous immunoglobulin. Br J Haematol. 2009;146(1):120–122. doi:10.1111/J.1365-2141.2009.07715.X
   PubMed Web of Science ®Google Scholar
• Zeevi A, Husain S, Spichty KJ, et al. Recovery of functional memory T cells in lung transplant recipients following induction therapy with alemtuzumab. Am J Transplant. 2007;7(2):471–475. doi:10.1111/J.1600-6143.2006.01641.X
   PubMed Web of Science ®Google Scholar
• Casulo C, Maragulia J, Zelenetz AD. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk. 2013;13(2):106. doi:10.1016/J.CLML.2012.11.011
   PubMed Web of Science ®Google Scholar
• Pritchard M. COVID-19 symptoms at hospital admission vary with age and sex: ISARIC multinational study. medRxiv Prepr Serv Heal Sci. 2020. doi:10.1101/2020.10.26.20219519
   Google Scholar
• Dananché C, Elias C, Hénaff L, et al. Baseline clinical features of COVID-19 patients, delay of hospital admission and clinical outcome: a complex relationship. PLoS One. 2022;17(1). doi:10.1371/JOURNAL.PONE.0261428
   PubMed Web of Science ®Google Scholar
• Sahraian MA, Azimi A, Navardi S, Ala S, Naser Moghadasi A. Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis. Mult Scler Relat Disord. 2020;46. doi:10.1016/J.MSARD.2020.102472
   Google Scholar